Dianthus Therapeutics to Participate in Two Upcoming Investor Events
Dianthus Therapeutics, a clinical-stage biotech company focused on developing antibody complement therapeutics for autoimmune diseases, has announced its participation in two major investor events.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dianthus Therapeutics, a clinical-stage biotech company focused on developing antibody complement therapeutics for autoimmune diseases, has announced its participation in two major investor events.
The company will be featured at:
- Baird Biotech Discovery Series - CEO Marino Garcia will join a fireside chat on May 6, 2025, at 1:30 p.m. EDT
- Bank of America 2025 Health Care Conference - Garcia will present a corporate overview on May 14, 2025, at 5:35 p.m. EDT and conduct one-on-one investor meetings
Both presentations will be accessible via webcast through the "News and Events" section of Dianthus Therapeutics' investor website.
Positive
- CEO's participation in two major healthcare investment conferences indicates strong institutional interest
- Company maintains active investor relations and market visibility through high-profile events
Negative
- None.
Details
News Market Reaction – DNTH
The recorded move for DNTH in the trading session of this news was +1.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company’s participation at two upcoming investor events.
- Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.
- Bank of America 2025 Health Care Conference – Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, May 14 at 5:35 p.m. EDT / 2:35 p.m. PDT and will host one-on-one meetings with investors.
Webcasts of these presentations may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.